No Data
Kangchen Pharmaceutical\'s 2024 Third Quarter Report
Beijing Konruns Pharmaceutical (603590.SH): The net income in the first three quarters is approximately 0.113 billion yuan, a decrease of 23.99% year-on-year.
Kang Chen Pharmaceuticals (603590.SH) announced on October 29th that its revenue for the first three quarters of 2024 was approximately 0.646 billion yuan, a decrease of 10.24% year-on-year; net income attributable to shareholders of the listed company was approximately 0.113 billion yuan, a decrease of 23.99% year-on-year; and the basic earnings per share was 0.7189 yuan.
Beijing konruns pharmaceutical (603590.SH): KC1036, an late-stage III clinical study for esophageal squamous cell carcinoma, is progressing in an orderly manner according to plan across multiple clinical trials.
GeLongHui October 8th | Beijing Konruns Pharmaceutical (603590.SH) stated during a specific object investigation that KC1036 has made diversified clinical breakthroughs, entering Phase III clinical research for advanced esophageal squamous cell carcinoma. KC1036 is a multi-target receptor tyrosine kinase inhibitor independently developed by the company, and is systematically conducting multiple clinical trials as planned, with a focus on treating advanced esophageal squamous cell carcinoma in Phase III clinical research, KC1036 combined with PD-1 antibodies for first-line maintenance treatment of locally advanced or metastatic esophageal squamous cell carcinoma, and KC1036 for treating late-stage Ewing sarcoma in adolescents aged 12 and above.
Beijing Konruns Pharmaceutical (603590): Core product sales have fluctuated, and the research and development of innovative drugs is steadily progressing.
Event: The company released its 2024 interim report, achieving revenue of 0.405 billion yuan (-10.16%), net income attributable to shareholders of listed companies 79.2 million yuan (-14.73%), attributable to shareholders of listed companies.
Beijing Konruns Pharmaceutical (603590): Performance under pressure, orderly advancement of the clinical pipeline.
Event: In the first half of 2024, the company achieved revenue of 0.405 billion yuan (-10.16% YoY), net income attributable to parent company of 0.079 billion yuan (-14.73% YoY), and net income attributable to parent company after non-recurring items of 0.074 billion yuan (-
Beijing Konruns Pharmaceutical (603590): KC1036 Phase III continues to progress, Jincaopian is about to apply for listing.
Event: The company released its 2024 interim report, achieving revenue of 0.41 billion yuan (-10.16%), net income attributable to the parent company's shareholders of 0.08 billion yuan (-14.73%), excluding non-recurring items attributable to shareholders of the listed company.
No Data
No Data